Feedback PLC Preliminary results from the Oxford Stone Group (8097M)
11 Mai 2015 - 4:09PM
UK Regulatory
TIDMFDBK
RNS Number : 8097M
Feedback PLC
11 May 2015
11 May 2015
Feedback plc
("Feedback" or the "Company")
Preliminary results from the Oxford Stone Group using TexRAD
research software in the analysis of kidney stones
Feedback plc (AIM: FDBK), the medical imaging software company,
previously announced on 13 April 2015 that it had signed a research
agreement with the Oxford Stone Group at the University of Oxford
& Oxford University Hospital NHS Trust ("Oxford"), UK to
investigate the potential future clinical application of Feedback's
TexRAD texture analysis software on computed tomography (CT) image
data of patients with kidney stones.
The preliminary results from a 38 patient retrospective study so
far are promising. Researchers at Oxford have demonstrated that
TexRAD texture analysis could identify from pre-treatment CT scans
which patients would have "successful" shockwave lithotripsy (SWL)
therapy from those who would have "unsuccessful" therapy.
The research was led by Mr Ben Turney (Bernard Senior Clinical
Researcher in Urology at the University of Oxford and Honorary
Consultant Urological Surgeon) and carried out by Mr Daniel Stevens
(Academic Clinical fellow in Urology at the University of
Oxford).
Mr Ben Turney, a leading authority on stone disease in the UK,
commented:
"Shock Wave Lithotripsy (SWL) is a well-established non-invasive
surgical procedure for urolithiasis. However around 30-40% of
patients do not achieve stone clearance and proceed to alternative
treatments. We have demonstrated in this first preliminary study
that TexRAD CT textural analysis appears to be an independent novel
predictive biomarker for SWL success. TexRAD CT texture analysis
may be a useful tool for risk-stratification and more accurately
triaging those patients who will benefit from SWL. The next step is
to undertake a prospective study to ascertain the clinical utility
of this finding in a large population. Additionally, we shall
explore other research questions such as assessing the stone
composition and differentiate between actual stones and those
conditions that mimic stone-like characteristics to increase
diagnostic confidence and prevent unnecessary costly investigation
and treatments."
Dr. Balaji Ganeshan, Chief Scientist & New Business Officer
of the Company's subsidiaries TexRAD Ltd & Cambridge Computed
Imaging Ltd commented:
"We are delighted with the positive results from the preliminary
study within a few weeks of signing the research agreement with Mr
Ben Turney and the team at Oxford. This is very encouraging news
and provides an opportunity for Feedback Plc to develop a TexRAD
based kidney stone software product dedicated to the management of
kidney stone patients."
Mr Ben Turney and team have further submitted their preliminary
results as an abstract for a possible presentation to the
Challenges in Endourology meeting
(http://www.challenges-endourology.com) in Paris in June 2015.
For further information contact:
Feedback plc Tel: 01954
718072
Simon Barrell / Trevor Brown
/ Tom Charlton
Sanlam Securities UK (Nominated Tel: 020 7628
Adviser and Joint Broker) 2200
Simon Clements / Virginia
Bull
Peterhouse Corporate Finance Tel: 020 7469
Ltd (Joint Broker) 0936
Lucy Williams / Duncan Vasey
Notes to editors:
TexRAD is a novel sophisticated imaging risk stratification
research tool that analyses the textures in existing radiological
scans. This research software application analyses textures,
detecting and measuring tumour heterogeneity (complexity) from
these images, revealing more information from medical images than
is readily visible to the naked eye. Research to date has shown
that TexRAD could potentially assist the clinician (as an
'Imaging-Biomarker') in confident decision-making: it has the
potential to assess the prognosis, disease-severity (e.g. risk of
metastases) and response evaluation of patients with cancer.
Currently TexRAD research has shown great potential in many
different oncological sites, including, colorectal, breast, lung,
prostate, oesophageal, head & neck, lymphoma, liver and renal
cancers and could potentially be employed as a heterogeneity
assessing tool in the era of 'Precision and Personalized Medicine'.
TexRAD is manufactured under licence by company Cambridge Computed
Imaging Ltd, a subsidiary of Feedback plc. More information is
available on www.fbk.com and www.texrad.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEALSFFEXSEFF
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jul 2023 bis Jul 2024